BioCentury | Oct 11, 2018
Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18 Selected developments and initiatives in 3Q18 from major sources of public funding including NIH , the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes of Health Research...
BioCentury | Jan 4, 2018
Strategy

Next generation resolutions

With a slew of landmark approvals in the last 18 months, FDA has solidified its commitment to advancing genetic diagnostics. Now the agency is turning to the outstanding challenges, with solutions on the horizon for...
BioCentury | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Oct 24, 2016
Company News

Celgene, Epic Sciences, Foundation Medicine, Genentech, Guardant Health, Personal Genome Diagnostics, Sage Bionetworks, Seven Bridges, Thermo Fisher, AstraZenec

The White House announced the Cancer Moonshot initiative will launch the Blood Profiling Atlas pilot to create an open database for liquid biopsies to develop blood profiling diagnostic technologies. The database will include raw datasets...
BioCentury | Oct 17, 2016
Politics & Policy

Cancer Moonshot report outlines new programs

The White House released its report of the Cancer Moonshot Task Force on Monday, announcing a slew of public and private partnerships to advance the goals of the Cancer Moonshot Initiative. The report also outlined...
BioCentury | Feb 22, 2016
Financial News

Seven Bridges completes venture financing

Seven Bridges Genomics Inc. , Cambridge, Mass. Business: Bioinformatics Date completed: 2016-02-16 Type: Venture financing Raised: $45 million Investor: Kryssen Capital WIR Staff...
BioCentury | Feb 17, 2016
Financial News

Seven Bridges closes $45M series A

Biomedical data analysis company Seven Bridges Genomics Inc. (Cambridge, Mass.) raised $45 million in a series A round led by Kryssen Capital. The company's Seven Bridges Platform comprises a cloud-based tools suite that allows academic,...
Items per page:
1 - 7 of 7
BioCentury | Oct 11, 2018
Translation in Brief

Public funding highlights: 3Q18

Public funding highlights: 3Q18 Selected developments and initiatives in 3Q18 from major sources of public funding including NIH , the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes of Health Research...
BioCentury | Jan 4, 2018
Strategy

Next generation resolutions

With a slew of landmark approvals in the last 18 months, FDA has solidified its commitment to advancing genetic diagnostics. Now the agency is turning to the outstanding challenges, with solutions on the horizon for...
BioCentury | Mar 21, 2017
Company News

Management tracks

The Relypsa Inc. gastrointestinal subsidiary of Galencia Ltd. (SIX:GALN) said President and CEO John Orwin will resign. Scott Garland will be promoted to president effective March 31, and Orwin's resignation as CEO will take effect...
BioCentury | Oct 24, 2016
Company News

Celgene, Epic Sciences, Foundation Medicine, Genentech, Guardant Health, Personal Genome Diagnostics, Sage Bionetworks, Seven Bridges, Thermo Fisher, AstraZenec

The White House announced the Cancer Moonshot initiative will launch the Blood Profiling Atlas pilot to create an open database for liquid biopsies to develop blood profiling diagnostic technologies. The database will include raw datasets...
BioCentury | Oct 17, 2016
Politics & Policy

Cancer Moonshot report outlines new programs

The White House released its report of the Cancer Moonshot Task Force on Monday, announcing a slew of public and private partnerships to advance the goals of the Cancer Moonshot Initiative. The report also outlined...
BioCentury | Feb 22, 2016
Financial News

Seven Bridges completes venture financing

Seven Bridges Genomics Inc. , Cambridge, Mass. Business: Bioinformatics Date completed: 2016-02-16 Type: Venture financing Raised: $45 million Investor: Kryssen Capital WIR Staff...
BioCentury | Feb 17, 2016
Financial News

Seven Bridges closes $45M series A

Biomedical data analysis company Seven Bridges Genomics Inc. (Cambridge, Mass.) raised $45 million in a series A round led by Kryssen Capital. The company's Seven Bridges Platform comprises a cloud-based tools suite that allows academic,...
Items per page:
1 - 7 of 7